Alemtuzumab (Anti-CD52) Biosimilar In Vivo Antibody
- SKU:
- IVMB0224
- Product Type:
- Biosimilar In Vivo Antibody
- Antibody Type:
- Monoclonal Antibody
- Protein:
- CD52
- Clone:
- Campath-1H
- Isotype:
- IgG1 kappa
- Reactivity:
- Human
- NHP - Rhesus Monkey
- NHP - Cynomolgus Monkey
- Synonyms:
- HE5, CDW52, EDDM5 CDW52, Cambridge pathology 1 antigen
Frequently bought together:
Description
system_update_altDatasheet
| Product Name: | Alemtuzumab (Anti-CD52) Biosimilar In Vivo Antibody |
| Product Code: | IVMB0224 |
| Clone: | Campath-1H |
| Protein: | CD52 |
| Product Type: | Biosimilar Recombinant Human Monoclonal Antibody |
| Synonyms: | HE5, CDW52, EDDM5 CDW52, Cambridge pathology 1 antigen |
| Isotype: | Human IgG1κ |
| Reactivity: | Human/Rhesus Monkey/Cynomolgus Monkey |
| Immunogen: | Human lymphocytes. |
| Applications: | CyTOF®, ELISA, FA, FC, IHC FF, IHC FFPE, WB |
| Formulation: | This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
| Endotoxin Level: | < 1.0 EU/mg as determined by the LAL method |
| Purity: | >95% by SDS-PAGE and HPLC |
| Preparation: | Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
| Storage and Handling: | Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
| Applications: | CyTOF®, ELISA, FA, FC, IHC FF, IHC FFPE, WB |
| Recommended Usage: | FC The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 µg per 106 in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application. |
| Reactivity: | Human/Rhesus Monkey/Cynomolgus Monkey |
| Specificity: | This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Alemtuzumab. Clone Campath-1H recognizes human CD52. This product is for research use only. |
| Antigen Distribution: | CD52 is primarily expressed on the surface of mature lymphocytes. Additionally, CD52 is present on most lymphoid derived malignancies. However, variable expression on Myeloma cells should be noted. |
| Immunogen: | Human lymphocytes. |
| Concentration: | ≥ 5.0 mg/ml |
| Endotoxin Level: | < 1.0 EU/mg as determined by the LAL method |
| Purity: | >95% by SDS-PAGE and HPLC |
| Formulation: | This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
| Preparation: | Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
| Storage and Handling: | Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
| Protein: | CD52 |
Related Products
Alemtuzumab (Anti-CD52) Biosimilar In Vivo Antibody (Fc Reduced)
Rituximab (Anti-CD20) Biosimilar In Vivo Antibody
Bevacizumab (Anti-VEGF) Biosimilar In Vivo Antibody
Oxelumab (Anti-OX40L) Biosimilar In Vivo Antibody
Cetuximab (Anti-EGFR) Biosimilar In Vivo Antibody
Adalimumab (Anti-TNF alpha) Biosimilar In Vivo Antibody
Sarilumab (Anti-IL-6) Biosimilar In Vivo Antibody
Tabalumab (Anti-CD257 / BAFF) Biosimilar In Vivo Antibody
